Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-01-16

Clinical Trial Update: Bifeprunox in the Treatment of Schizophrenia [Phase 3]

View source ↗

Summary

The Phase 3 clinical trial evaluating bifeprunox for schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bifeprunox (bifeprunox)

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED